Toll-like receptor 9 is correlated to disease activity in Chinese systemic lupus erythematosus population

Chinese Medical Journal

Volumn 125, Issue 16, 2012, Pages 2873-2877

  Mu, Rong ^a   Sun, Xiao yun ^b   Lim, Lik Thai ^c   Xu, Chuan hui ^a   Dai, Chen xian ^a   Su, Yin ^a   Jia, Ru lin ^a   Li, Zhan guo ^a  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^b PFIZER INC   (United States)

^c GARTNAVEL GENERAL HOSPITAL   (United Kingdom)

Author keywords

Interferon alpha; Interferon regulatory factor 5; Systemic lupus erythematosus; Toll like receptor 9

Indexed keywords

ALPHA INTERFERON; AUTOANTIBODY; DOUBLE STRANDED DNA ANTIBODY; ESTROGEN; INTERFERON REGULATORY FACTOR 5; TOLL LIKE RECEPTOR 9;

ADULT; ALOPECIA; ARTHRALGIA; ARTICLE; CHINESE; CONTROLLED STUDY; DISEASE ACTIVITY; EDEMA; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FEVER; HUMAN; HUMAN CELL; KIDNEY DISEASE; LUPUS ERYTHEMATOSUS; MAJOR CLINICAL STUDY; MALE; MOUTH ULCER; PERIPHERAL BLOOD MONONUCLEAR CELL; PHOTOSENSITIVITY; PROTEIN EXPRESSION; RASH; RAYNAUD PHENOMENON; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADOLESCENT; ADULT; ANTIBODIES, ANTINUCLEAR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INTERFERON REGULATORY FACTORS; INTERFERON-ALPHA; LEUKOCYTES, MONONUCLEAR; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; REAL-TIME POLYMERASE CHAIN REACTION; TOLL-LIKE RECEPTOR 9; YOUNG ADULT;

EID: 84865395359     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2012.16.014     Document Type: Article

References (36)

1. D'Cruz DP, Khamashta MA, Hughes GRV. Systemic lupus erythematosus. Lancet 2007; 369: 587-596.
2. Rahman A, Isenberg DA. Systemic lupus erythematosus. N Engl J Med 2008; 358: 929-939.
3. Anders HJ. A toll for lupus. Lupus 2005; 14: 417-422.
4. Lafyatis R, Marshak-Rothstein A. Toll-like receptors and innate immune responses in systemic lupus erythematosus. Arthritis Res Ther 2007; 9: 222-228.
5. Martin DA, Elkon KB. Autoantibodies make a U-turn: the toll hypothesis for autoantibody specificity. J Exp Med 2005; 202: 1465-1469.
6. Akira S, Takeda K, Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol 2001; 2: 675-680.
7. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006; 124: 783-801.
8. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol 2003; 21: 335-376.
9. Christensen SR, Kashgarian M, Alexopoulou L, Flavell RA, Akira S, Shlomchik MJ. Toll-like receptor 9 controls anti-DNA autoantibody production in murine lupus. J Exp Med 2005; 202: 321-331.
10. Christensen SR, Shupe J, Nickerson K, Kashgarian M, Flavell RA, Shlomchik MJ. Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. Immunity 2006; 25: 417-428.
11. Sato Y, Miyata M, Nishimaki T, Kochi H, Kasukawa R. CpG motif-containing DNA fragments from sera of patients with systemic lupus erythematosus proliferate mononuclear cells in vitro. J Rheumatol 1999; 26: 294-301.
12. Crow MK. Type I interferon in systemic lupus erythematosus. Curr Top Microbiol Immunol 2007; 316: 359-386.
13. Rönnblom L, Pascual V. The innate immune system in SLE: type I interferons and dendritic cells. Lupus 2008; 17: 394-399.
14. Hooks JJ, Moutsopoulos HM, Geis SA, Stahl NI, Decker JL, Notkins AL. Immune interferon in the circulation of patients with autoimmune disease. N Engl J Med 1979; 301: 5-8.
15. Rönnblom L, Alm GV, Öberg KE. Possible induction of systemic lupus erythematosus by interferon-α treatment in a patient with a malignant carcinoid tumour. J Intern Med 1990; 227: 207-210.
16. Fukuyama S, Kajiwara E, Suzuki N, Miyazaki N, Sadoshima S, Onoyama K. Systemic lupus erythematosus after [alpha]-interferon therapy for chronic hepatitis c: a case report and review of the literature. Am J Gastroenterol 2000; 95: 310-312.
17. Graham RR, Kozyrev SV, Baechler EC, Reddy MVPL, Plenge RM, Bauer JW, et al. A common haplotype of interferon regulatory factor 5 (IRF5) regulates splicing and expression and is associated with increased risk of systemic lupus erythematosus. Nat Genet 2006; 38: 550-555.
18. Takaoka A, Yanai H, Kondo S, Duncan G, Negishi H, Mizutani T, et al. Integral role of IRF-5 in the gene induction programme activated by Toll-like receptors. Nature 2005; 434: 243-249.
19. Komatsuda A, Wakui H, Iwamoto K, Ozawa M, Togashi M, Masai R, et al. Up-regulated expression of Toll-like receptors mRNAs in peripheral blood mononuclear cells from patients with systemic lupus erythematosus. Clin Exp Immunol 2008; 152: 482-487.
20. Migita K, Miyashita T, Maeda Y, Nakamura M, Yatsuhashi H, Kimura H, et al. Toll-like receptor expression in lupus peripheral blood mononuclear cells. J Rheumatol 2007; 34: 493-500.
21. Papadimitraki ED, Choulaki C, Koutala E, Bertsias G, Tsatsanis C, Gergianaki I, et al. Expansion of toll-like receptor 9-expressing B cells in active systemic lupus erythematosus: implications for the induction and maintenance of the autoimmune process. Arthritis Rheum 2006; 54: 3601-3611.
22. Richez C, Blanco P, Rifkin I, Moreau JF, Schaeverbeke T. Role for toll-like receptors in autoimmune disease: the example of systemic lupus erythematosus. Joint Bone Spine 2011; 78: 124-130.
23. Barrat FJ, Meeker T, Chan JH, Guiducci C, Coffman RL. Treatment of lupus-prone mice with a dual inhibitor of TLR7 and TLR9 leads to reduction of autoantibody production and amelioration of disease symptoms. Eur J Immunol 2007; 37: 3582-3586.
24. Tao K, Fujii M, Tsukumo S, Maekawa Y, Kishihara K, Kimoto Y, et al. Genetic variations of toll-like receptor 9 predispose to systemic lupus erythematosus in Japanese population. Ann Rheum Dis 2007; 66: 905-909.
25. Wu O, Chen GP, Chen H, Li XP, Xu JH, Zhao SS, et al. The expressions of toll-like receptor 9 and T-bet in circulating B and T cells in newly diagnosed, untreated systemic lupus erythematosus and correlations with disease activity and laboratory data in a Chinese population. Immunobiology 2009; 214: 392-402.
26. ter Borg EJ, Horst G, Hummel EJ, Limburg PC, Kallenberg CG. Measurement of increases in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus. A long-term, prospective study. Arthritis Rheum 1990; 33: 634-643.
27. Dall'Era MC, Cardarelli PM, Preston BT, Witte A, Davis JC. Type I interferon correlates with serological and clinical manifestations of SLE. Ann Rheum Dis 2005; 64: 1692-1697.
28. Nakano S, Morimoto S, Suzuki J, Nozawa K, Amano H, Tokano Y, et al. Role of pathogenic auto-antibody production by Toll-like receptor 9 of B cells in active systemic lupus erythematosus. Rheumatology 2008; 47: 145-149.
29. Yasuda K, Richez C, Uccellini MB, Richards RJ, Bonegio RG, Akira S, et al. Requirement for DNA CpG content in TLR9-dependent dendritic cell activation induced by DNA-containing immune complexes. J Immunol 2009; 183: 3109-3117.
30. Duramad O, Fearon KL, Chang B, Chan JH, Gregorio J, Coffman RL, et al. Inhibitors of TLR-9 act on multiple cell subsets in mouse and man in vitro and prevent death in vivo from systemic inflammation. J Immunol 2005; 174: 5193-5200.
31. Leadbetter EA, Rifkin IR, Hohlbaum AM, Beaudette BC, Shlomchik MJ, Marshak-Rothstein A. Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature 2002; 416: 603-607.
32. Lin L, Gerth AJ, Peng SL. CpG DNA redirects class-switching towards "Th1-like" Ig isotype production via TLR9 and MyD88. Eur J Immunol 2004; 34: 1483-1487.
33. Liu N, Ohnishi N, Ni L, Akira S, Bacon KB. CpG directly induces T-bet expression and inhibits IgG1 and IgE switching in B cells. Nat Immunol 2003; 4: 687-693.
34. Lartigue A, Colliou N, Calbo S, Francois A, Jacquot S, Arnoult C, et al. Critical role of TLR2 and TLR4 in autoantibody production and glomerulonephritis in lpr mutation-induced mouse lupus. J Immunol 2009; 183: 6207-6216.
35. Preble OT, Black RJ, Friedman RM, Klippel JH, Vicek J. Systemic lupus erythematosus: presence in human serum of an unusual acid-labile leukocyte interferon. Science 1982; 216: 429-431.
36. Savitsky DA, Yanai H, Tamura T, Taniguchi T, Honda K. Contribution of IRF5 in B cells to the development of murine SLE-like disease through its transcriptional control of the IgG2a locus. Proc Natl Acad Sci U S A 2010; 107: 10154-10159.